Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
News|Articles|April 10, 2015
Baxter Recalls IV Solutions
Author(s)Pharmaceutical Technology Editors
Baxter voluntarily recalls select lots of IV solutions due to possible particulate matter.
Advertisement
FDA reported on April 9, 2015 that Baxter International has voluntarily recalled select lots of intravenous (IV) solutions for possible particulate matter. The IV solutions include Sodium Chloride Injection, USP, indicated as a source of water and electrolytes and for use as a priming solution in hemodialysis procedures; Dextrose Injection, USP, indicated as a source of water and calories; and Lactated Ringer’s Injection, USP, indicated as a source of water and electrolytes, or as an alkalinizing agent. The recalled lots were distributed in the United States and Bermuda between Jan. 14, 2015 and March 5, 2015.
Baxter personnel discovered the particulates while performing routine maintenance and identified the particulates as material from a solution transmission system pump. The company has not yet received any adverse event reports or complaints.
A
Source:
Advertisement
Related to this article
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
AI can turn medical device risk management into a continuous signal.
On PharmTech.com this week, coverage of upcoming events continued, experts continued to discuss the use of AI in pharma, and validation in oral solid dosage product production was emphasized.
This article explores the historical use of silicone oil in the performance of primary drug product packaging; design of experiment test results for selection of the cleaning agent and CCPs; assessment of visible residue limits and Fourier-transform infrared spectroscopy surface analysis; and setting health-based exposure limits for silicone oil using a non-uniform distribution model, and a previously published permitted daily exposure.
In commercial tablet or capsule operations, validation helps protect the site’s ability to produce, release, and supply product without repeated disruption. This article discusses validation as a technical control system that supports manufacturing continuity.
This article explains the 4 shifts enabling faster, lower-risk, commercially successful biologics technology transfer.
Advertisement
Advertisement